A

Akero Therapeutics
D

AKRO

53.795
USD
0.09
(0.16%)
مغلق
حجم التداول
18,266
الربح لكل سهم
-4
العائد الربحي
-
P/E
-14
حجم السوق
4,312,466,599
أصول ذات صلة الأخبار المقالات

العنوان: Akero Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.